Fortrea Holdings ($FTRE) Overstated EBITDA Targets, Spin-Off Missteps, and Post-Merger Collapse Case
$FTRE investors filed a claim against Fortrea Holdings for inflating 2025 financial projections and misleading investors about revenue from inherited projects and cost savings from its Labcorp spin-off.
After Fortrea admitted that its forecasts were unrealistic and revealed lower profitability from legacy contracts, $FTRE fell a total of 41.4%, including a 25% drop on March 3, 2025.
$FTRE investors can join this case to be notified about potential recovery.
Case Details:
Between July 3, 2023 and February 28, 2025, Fortrea promoted its post-spin business as a focused, efficient contract research organization (CRO) capable of expanding margins by replacing Labcorp’s shared infrastructure and generating high-value new contracts. Executives repeatedly claimed 2025 EBITDA margins would reach 13%, later lowered slightly to 11–12%, and assured investors that transitional service agreements (TSAs) would be phased out with strong cost savings.
In truth, Fortrea grossly overestimated revenue from legacy Labcorp projects and understated the actual costs of exiting TSAs. By late 2024, analysts were warning that IT replacement costs were being masked and cost savings overstated. Internal reviews revealed that many pre-spin contracts were late-stage, low-margin projects, and new business growth wasn’t fast enough to fill the gap.
On September 25, 2024, Jefferies downgraded $FTRE, citing weak biotech funding, limited margin expansion, and inflated expectations. $FTRE fell 12.29%. On December 6, 2024, Fortrea abruptly cancelled two investor conferences, prompting Baird to issue a downgrade over transparency concerns, causing $FTRE to drop 8.06%. Finally, on March 3, 2025, the company admitted that 2025 revenue and margins would fall short of expectations due to weaker-than-expected pre-spin project performance. $FTRE plunged 25.05%.
Based on these events, $FTRE investors filed a claim against Fortrea Holdings, accusing the company of the following:
It inflated projected revenue and EBITDA by misrepresenting the contribution of inherited Labcorp contracts.
It misled investors about the cost structure and savings from exiting TSAs.
It failed to correct internal forecasts despite knowing that its 2025 guidance was unachievable.
Considering all the representations, investors believe Fortrea misled the market about its financial health and post-spin strategy to sustain valuation and executive credibility.